Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 9;60(1):686-8.
doi: 10.1128/AAC.02437-15. Print 2016 Jan.

fosI Is a New Integron-Associated Gene Cassette Encoding Reduced Susceptibility to Fosfomycin

Karla de Oliveira Pelegrino  1 , Juliana Coutinho Campos  2 , Suely Carlos Ferreira Sampaio  3 , Karina Lezirovitz  4 , Bruna Mara Seco  2 , Mayne de Oliveira Pereira  2 , Darlan Augusto da Costa Rocha  2 , Thomas Jové  5 , Antonio Carlos Nicodemo  1 , Jorge Luiz Mello Sampaio  6
Affiliations

fosI Is a New Integron-Associated Gene Cassette Encoding Reduced Susceptibility to Fosfomycin

Karla de Oliveira Pelegrino et al. Antimicrob Agents Chemother. .

Abstract

In this work, we demonstrate that the fosI gene encodes a predicted small protein with 134 amino acids and determines reduced susceptibility to fosfomycin. It raised the MIC from 0.125 to 6 μg/ml when the pBRA100 plasmid was introduced into Escherichia coli TOP10 and to 16 μg/ml when the gene was cloned into the pBC_SK(-) vector and expressed in E. coli TOP10.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(A) Structure of the fosI cassette. Inverted repeats are shaded gray. The numbers refer to base pair coordinates in the sequence with GenBank accession no. CP003505. Only the coding strand is shown. (B) Alignment of amino acid sequences of Fos proteins. After each protein name is the GenBank accession number. The arrows indicate key conserved amino acids/metal binding sites. Fos protein designations (FosE, FosF, FosG, and FosH) are according to the RAC database (20).
See this image and copyright information in PMC

References

    1. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. 1974. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 235:364–386. doi:10.1111/j.1749-6632.1974.tb43277.x. - DOI - PubMed
    1. Neuner EA, Sekeres J, Hall GS, van Duin D. 2012. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 56:5744–5748. doi:10.1128/AAC.00402-12. - DOI - PMC - PubMed
    1. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. 2014. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 43:52–59. doi:10.1016/j.ijantimicag.2013.09.010. - DOI - PubMed
    1. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM Jr, Ritchie DJ. 2012. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 34:1314–1323. doi:10.1016/j.clinthera.2012.05.002. - DOI - PMC - PubMed
    1. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. 2012. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31:695–701. doi:10.1007/s10096-011-1360-5. - DOI - PubMed

Publication types

Associated data